Alaunos Therapeutics (Alaunos Therapeutics) FCF Margin % : -738,500.00% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alaunos Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-7.39 Mil. Alaunos Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Alaunos Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -738,500.00%.

As of today, Alaunos Therapeutics's current FCF Yield % is -143.54%.

The historical rank and industry rank for Alaunos Therapeutics's FCF Margin % or its related term are showing as below:

TCRT' s FCF Margin % Range Over the Past 10 Years
Min: -606780 Med: -1845.6 Max: -9.74
Current: -606780

During the past 13 years, the highest FCF Margin % of Alaunos Therapeutics was -9.74%. The lowest was -606780.00%. And the median was -1845.60%.

TCRT's FCF Margin % is ranked worse than
99.32% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs TCRT: -606780.00

Alaunos Therapeutics FCF Margin % Historical Data

The historical data trend for Alaunos Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics FCF Margin % Chart

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-16,279.15

-1,007.80

-606,780.00

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-65,872.73	-	-178,425.00	-	-738,500.00

Competitive Comparison of Alaunos Therapeutics's FCF Margin %

For the Biotechnology subindustry, Alaunos Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alaunos Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's FCF Margin % falls into.

Alaunos Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alaunos Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-30.339	/	0.005
	=	-606,780.00 %

Alaunos Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.385	/	0.001
	=	-738,500.00 %

Alaunos Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Executives

Boyle Kevin S. Sr.	director, officer: Chief Executive Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser	director	ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma	director	141 MECOX ROAD, WATER MILL NY 11976
Michael Wong	officer: VP, Finance	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava	officer: See Remarks	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis	director	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden	director	38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger	officer: VP, Research & Development	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De	officer: EVP, Operations	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey	officer: Senior Vice President, Legal	C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen	director	AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa	officer: Chief Medical Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129